• Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, ……Wilson KC et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. AJRCCM May 01, 2022, Vol 205, issue 09

  • Full Text
  • Supplements
  • Abstract
  • PDF
• Press release

  • New Clinical Practice Guideline on Idiopathic Pulmonary Fibrosis (update) and Progressive Pulmonary Fibrosis in Adults

• Letters to editor
  • Moran-Mendoza O. Idiopathic Pulmonary Fibrosis Update: Reconciliation with Hypersensitivity Pneumonitis Guidelines Required? AJRCCM published online June 07, 2022, Vol 202, Issue 2. PDF

  • Ragu G, Richeldi L, Remy-Jardin M, Thomson CC, Wilson KC. Reply to: Idiopathic Pulmonary Fibrosis Update: Reconciliation with Hypersensitivity Pneumonitis Guidelines Required? AJRCCM published online June 07, 2022, Vol 202, Issue 2

     

• Clinician summary

  • Hermann DD, Ghazipura M, Raghu G, Richeldi L, Remy-Jardin M, Ruminjo JK and Thomson CC. Summary for Clinicians: Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults. Annals ATS, Feb 2023

     

• Systematic reviews

  • Kheir F, Becerra JPU, Bissell B, Ghazipura M, Herman D, Hon SM,….Wilson KC, et al. Transbronchial Lung Cryobiopsy in Patients with Interstitial Lung Disease: A Systematic Review. Annals ATS Vol 19, Issue 07, July 01, 2022

  • Ghazipura M, Mammen MJ, Bissell BD, Macrea M, Herman DD, Hon SM…….Wilson KC, et al. Pirfenidone in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Annals ATS Vol 19, Issue 06, June 01, 2022

  • Ghazipura M, Mammen MJ, Herman DD, Hon SM, Bissell BD, Macrea M…….Wilson KC, et al. Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Annals ATS Vol 19, Issue 06, June 01, 2022

  • Kheir F, Becerra JPU, Bissell B, Ghazipura M, Herman DD, Hon SM…… and Wilson KC, et al. Use of a Genomic Classifier in Patients with Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Annals ATS Vol 19, Issue 05, May 01, 2022

  • Khor YH, Bissel B, Ghazipura M, Herman D, Hon SM, Hossein… Wilson KC et al. Antacid Medication and Antireflux Surgery in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Annals ATS Vol 19, Issue 05, 2022

     

• CME/MOC questions

  • Summary for Clinicians: Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults

• Scientific symposia
  • In separate Clinical Expert Panel:

    • Raghu G, Wilson KC, Richeldi L et al. Highlights of the New Official 2022 ATS/ERS/JRS/ALAT Clinical Practice Guideline on Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults

    • Session on Clinical Topics in Pulmonary Medicine, Moscone South Building, Clinician Center. C2. PRO/CON: Interstitial Lung Disease Diagnosis and Management. May 17, 2022: 930 am – 1100 am

• Patient/Fam Ed

  • ATS Patient Education Series

    • Guler SA, Lindel KO, Swigris J and Ryerson C. What is Idiopathic Pulmonary Fibrosis? Part 1

    • Guler SA, Lindel KO, Swigris J and Ryerson C. Idiopathic Pulmonary Fibrosis. Part 2, Medications

    • Guler SA, Lindel KO, Swigris J and Ryerson C. Idiopathic Pulmonary Fibrosis. Part 3 Nondrug Treatments

• Pocket cards/guides
  • Flipbook
  • Shop link
• Reddit
• Clinician video

  • IPF (an update) and PPF in Adults

Complimentary Materials

• Related editorial

  • Marinescu D and Churg A. Impact of Lung Biopsy Information on Treatment Strategy of Patients with Interstitial Lung Diseases: The Glass is Half Full. Annals ATS Vol 19 Issue 05, May 01, 2022

  • Bowman WS and Dempsey T. Works in Progress: Using Administrative Data to Estimate the Prevalence of Progressive Fibrosing Interstitial Lung Disease. Annals ATS Vol 19, Issue 07, July 01, 2022

  • Singer D, Bengtson LGS, Conoscenti CS, Laouri M, Shetty SS, Anderson AJ and Brown KK. Claims- based Prevalence of Disease Progression Among Patients With Fibrosing Interstitial Lung Disease other than Idiopathic Pulmonary Fibrosis in the United States. Annals ATS Vol 19, Issue 07, July 01, 2022

  • Maher TM. Small Airways in Idiopathic Pulmonary Fibrosis: Quiet but Not Forgotten. AJRCCM Vol 204, Issue 9, Nov 01, 2021

  • Yang MM and Wolters PJ. Cut From the Same Cloth: Similarities between Hypersensitivity Pneumonitis and Idiopathic Pulmonary Fibrosis. AJRCCM Vol 205. Issue 01, Jan 01, 2022

  • Sgalla G, Wijsenbeek MS and Richeldi L. The Shorter, the Better: Can we Improve Efficiency of Idiopathic Pulmonary Fibrosis Trials? AJRCCM Vol 205, Issue 8, 2022

  • Bonham CA and Noth I. Idiopathic Pulmonary Fibrosis Genetic Factors, Function and Mechanisms: The Concepts Are Starting to Gel. AJRCCM Vol 206, Issue 10, 2022

  • Cottin V. Criteria for Progressive Pulmonary Fibrosis: Getting the Horse Ready for the Cart. AJRCCM Vol 207, Issue 1, Jan 01, 2023

  • Collins BF. Screening for Preclinical Pulmonary Fibrosis: Are We there yet? AJRCCM Vol 207, Issue 05, Mar 01, 2022

  • Wells AU. Analyses of the Efficacy and Safety of Antifibrotic Therapies in Non-IPF Pulmonary Fibrosis, Progressing Despite Management. AnnalsATS Vol 19, Issue 06, 2022

• Related systematic review

  • Wells AU. Analyses of the Efficacy and Safety of Anti-Fibrotic Therapies in non- IPF Pulmonary Fibrosis, Progressing despite Treatment. Annals ATS Vol 19, Issue 06

• Related focused review

  • Warrior K, Chung PA, Reid M and Bermiss BC. Use of Nintedanib and Pirfenidone in Non-Idiopathic Pulmonary Fibrosis Lung Disease. AJRCCM Vol 204 Issue 01, July 01, 2021

• Related update/viewpoint/perspective

  • Cottin V, Tomasseti S, Valenzuela C, Walsh SLF, Antoniou KM, Bonella F….and Ryerson CJ. Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. AJRCCM Vol 206, Issue 03, August 01, 2022

  • Aranson KI, Danoff SK, Russel AM, Ryerson CJ, Suzuki A, Wijsenbeek MS, Bajwah S and Swigris A. Patient Centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. AJRCCM Vol 204 issue 2, July 15, 2021

  • Cottin V, Selman M, Inoue Y, Wong AW, Corte TJ, Flaherty KR…and Wells AO. Syndrome of Combined Pulmonary Fibrosis and Emphysema: Research Statement. AJRCCM Vol 206, Issue 4, Aug 15, 2022

  • Stancil IT, Michalski JE and Schwartz DA. An Airway-Centric View of Idiopathic Pulmonary Fibrosis. AJRCCM Vol 206, Issue 4, Aug 15, 2022

  • Pugashetti JV, Adegunsoye A, Wu Z, Lee CT, Srikrishnan A, Ghodrati S et al. Validation of Proposed Criteria for Progressive Pulmonary Fibrosis. AJRCCM Vol 207, Issue 01 , Jan 01, 2022

  • Kamp JC, Werlein C, Plucinski EKJ, Neubert L, Welte T, Lee PD et al. Novel Insight into Pulmonary Fibrosis and Long Covid. AJRCCM Vol, Issue, published online Feb 02, 2023

• Related correspondence

  • Sgalia G, Magri T, Lerede M, Comes A and Richeldi L. Covid -19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis. AJRCCM Vol 206, Issue 2, July 15, 2022

  • Frank AL. Possible Alternate Explanation for Cases of Idiopathic Pulmonary Fibrosis. Annals ATS Vol 10, Issue 06, June 01, 2022

  • Kaul B, Lee JS, Collard HR and Whooley MA. Reply: Possible Alternate Explanation for Cases of Idiopathic Pulmonary Fibrosis. Annals ATS Vol 10, Issue 06, June 01, 2022

  • Takei R, Yamano Y, Kataoka K, Yokoyama T, Matsuda T, Kimura T, et al. New Guideline Diagnosis of Fibrotic Hypersensitivity Pneumonitis in Idiopathic Pulmonary Fibrosis. AJRCCM Vol 204 Issue 5, Sept 01, 2021

  • Huang J and Wei JCC. Postvaccination Acute Exacerbations in Idiopathic Pulmonary Fibrosis? AJRCCM, Vol 206, Issue 07, Oct 01, 2022

  • Sgalla G and Richeldi L on behalf of all authors. Reply to Huang and Wei; Kang et al; Ehteshami-Afshar and Raj. AJRCCM Vol 206, Issue 7, Oct 01, 2022

  • Boente RD, White EN, Baxter CM, Shore JE, Collard HR and Lee JS; PFF Best Practices Committee. Differences in Patient Outcomes across the Pulmonary Fibrosis Care Center Network. AJRCCM Vol 207, Issue 02, 2022

  • Noboa-Sevilla M, Hernandez-Gonzalez F, Alsina-Restoy X, Perez-Rodas N and Sellares J. Functional Criteria to Define Progressive Pulmonary Fibrosis; Searching for the Holy Grail. AJRCCM Vol 207, Issue 03, 2022

  • Khor Y, Farooqi M, Hambly N, Kolb M and Ryerson CJ,. Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions. AJRCCM Vol 207, Issue 01, Jan 01, 2022

  • Grewal JS, Fisher JH and Ryerson CJ. An Updated Assessment of Online Information on IPF. Annals ATS Vol 18, Issue 08, Aug 2021

• Related PHI

  • Ong S, Koo J, Johannson KA, Ryerson CJ and Goobie GC:. Content Analysis of Idiopathic Pulmonary Fibrosis-related Information on Twitter. ATS Scholar, Vol 3, issue 4, October 2022

• Related webinar

  • Pulmonary Fibrosis Foundation. PFF Disease Education Webinar Series. Lung Disease Week at the ATS. Symptom Management in Pulmonary Fibrosis. Sept 23, 2020

  • Pulmonary Fibrosis Foundation. Dr. Anna Podolanczuc. PFF: What Patients Need to Know. Sept 14, 2022

  • PFF Webinar Library. Drs. Amy Hajari Case, Kevin Flaherty and Joseph Lasky. Ask a Doc: PFF Medical Team Members Answer Your Questions. May 25, 2022

  • Pulmonary Fibrosis Foundation. Drs. Amy Hajari Case and Stephen Hobbs. Diagnosing ILD: Elements of a Comprehensive Evaluation. Jan 25, 2023

Pulmonary Fibrosis Foundation (PFF) is an ATS Public Advisory Roundtable (PAR) partner. 

Disclaimer: The ATS did not participate in the development of all the videos and has not formally reviewed or endorsed them